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Poster Session I S255combination with Cy 1500mg/m2 (Vino-Cy) is also an effective mo-
bilization regimen which is postulated to be better tolerated.
There have been no studies to our knowledge comparing Vino –
Cy with Cy as a mobilization regimen. In our institution, Cy with
GCSF was the mobilization regimen of choice before 2007. Vinor-
elbine - Cy gained preference since late 2006.We performed a retro-
spective analysis of mobilisation outcomes using Vino- Cy at the
doses described above compared to Cy at our institution.
Methods: Patient data was extracted from our institutional database.
Eight patients underwent mobilization using the Cy-GCSF regimen
while 37 patients had Vino-Cymobilization using GCSF or Pegfilgras-
tim.
Results:The median age of the Vino-Cy patients at the time of har-
vest was 54 years, 12 patients were female and the median weight was
60.5 Kg. Themedian age of the Cy patients was 55 years and two pa-
tients were female, the median weight was 60 Kg. A greater median
CD34+ stem cell collection and a shorter median time to completion
of harvest was seen using Vino-Cy compared to Cy (Table 1). There
was also minimal variability in the timing of the harvest for the Vino-
Cy group as suggested by a standard deviation of 0.63.
Table. Mobilisation Outcomes with Vino-Cy and Cy
Day of Protocol No. of Days taken
Harvest Took Place to harvestCyCD34+/KgCyVino-Cy Vino-Cy Vino-CyMedian 9 2 3 12.8 5.5
Mean 8.5 1.8 2.4 13.2 7.8
Minimum 7 1 1 5.4 0.48
Maximum 9 3 0.94 32.5 6.39Discussion. Our data suggest that vinorelbine-Cy is superior to
Cy based on the higher CD34+ stem cell collection (more than ade-
quate for tandem transplant) and earlier completion of harvesting.
The timing of harvest is also highly predictable with Vino-Cy. Pro-
spective analyses are required to determine if Vinorelbine-Cy mobi-
lization confers a survival benefit over Cy.137
THROMBOTICMICROANGIOPATHY (TMA) RELATED TO CYTOMEGALOVI-
RUS (CMV) IS A RARE BUT SERIOUS CONDITION AFTER AUTOLOGOUS
HEMATOPOIETIC STEM CELL TRANSPLANTATION (ASCT)
Katragadda, L.1, Alejandro, R.1, Muzaffar, J.1, Kumar, N. Sanath1,
Barlogie, B.1, Cottler-Fox, M.2, Anaissie, E.J.1 1University of Arkansas
for Medical Sciences, Little Rock, AR; 2University of Arkansas for Medical
Sciences, Little Rock, AR
Introduction:TMA is a rare condition that has been associated with
CMV infection in solid organ and allogeneic stem cell transplant re-
cipients. Very little is known about TMA in ASCT recipients.
Methods: We retrospectively reviewed the medical records of all
ASCT recipients at our institution between April 2008 and June
2010 with a positive quantitative plasma polymerase chain reaction
test (qPCR) for CMV deoxyribonucleic acid (DNA). For a diagnosis
of CMV-related TMA we required the presence of schistocytes on
peripheral smear, laboratory evidence of hemolysis and ongoing
CMV infection. We excluded those with other known causes for
TMA (disseminated intravascular coagulation, drugs, malignant hy-
pertension and others).
Results: During the time period examined, 1254 patients with he-
matological cancer underwent melphalan-based ASCT. Reactiva-
tion of CMV was documented in 190 patients (131 within the first
6 months after ASCT, and 59 .6 months after ASCT while receiv-
ing non-myeloablative chemotherapy). Peripheral schistocytosis was
noted in 18 of the 190 patients (9.5%) of whom 13were excluded due
to the presence of other potential causes of TMA, leaving 5 patients
qualified as having CMV-related TMA. All 5 patients had multiple
myeloma, with a median age of 56 years (range 48-67 years), and
a male to female ratio of 2:3. CMV-related TMA developed at a me-
dian of 21 days after ASCT and presented with altered mental status
(3), acute renal failure requiring hemodialysis (3), hepatitis (2), myo-
cardial infarction, bilateral ischemic stroke (1). The clinical manifes-tations of CMV infection in these five patients included
thrombocytopenia (5), fever (4), diarrhea (4), pancytopenia (3) and
pneumonitis (1). The mean CMV qPCR at TMA diagnosis was
7250 DNA copies/ml (range 1250 to 11800 DNA copies/ml). Three
patients died at a mean of eight days after diagnosis (range 5-13 days)
with persistent CMV infection by CMV qPCR while receiving gan-
ciclovir and/or foscarnet. One of the two survivors responded to gan-
ciclovir alone while the other patient received ganciclovir and
rituximab and underwent plasmapheresis. Both survivors cleared
their CMV infection.
Conclusion:CMV-relatedTMA is a rare but serious and potentially
fatal complication in ASCT recipients. This condition should be
considered in the differential diagnosis of TMA because timely ini-
tiation of anti-viral therapy may improve outcome.138
INFECTIONS FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION
FOR HODGKIN’S LYMPHOMA
Seo, S.1, Kimball, L.E.1, Xie, H.2, Weiss, A.A.1, Dahlgren, C.1,
Davis, C.2, Boeckh, M.J.1,2,3, Pergam, S.A.1,2,3 1Fred Hutchinson Cancer
Research Center, Seattle, WA; 2Fred Hutchinson Cancer Research Center,
Seattle, WA; 3University of Washington, Seattle, WA
Background: Autologous stem cell transplantation (ASCT) is
a treatment option for refractory or relapsed Hodgkin lymphoma
(HL). The epidemiology of infectious complications following
ASCT in this population are unknown, thus we set out to identify
the incidence and prevalence of infections in patients with HL re-
ceiving an ASCT.
Patients and Methods: We retrospectively reviewed records from
patients who underwent ASCT for HL at our institution between 1/
1996 and 8/2009. Patients received acyclovir, neutropenic and PCP
prophylaxis and weremonitoredweekly for pp65 antigenemia early af-
ter ASCT.The probability of infections was assessed using cumulative
incidence estimates and incidence rates were calculated with 95% con-
fidence intervals (CI) estimated using a Poisson distribution.
Results: A total of 171 patients had a median of 673 days of follow-
up post-ASCT (range: 357-1592 days). There were a total of 622 in-
fections that occurred in 151 patients (89%), of which 323/622
(51.9%) were proven/probable cases. The cumulative incidence of
any infection was 58% at 90 days and 81% at 1 year after ASCT.
In the early period, bacteremia and CMV pp65 antigenemia were
most frequent, occurring in 29% and 31% (CMV seropositives) re-
spectively by day 90. Serious invasive infections occurred in 20/177
(11%) patients (24 total infections: GNR bacteremia 7; invasive fun-
gal disease 6; lower tract infection 5; typhlitis 2; CMV disease 2;
HHV-6 encephalitis 1; PCP 1). Sinopulmonary infections made up
more than 50% of all events, with cumulative incidence ranging
from 17% (sinusitis) to 15% (respiratory virus infections) at 1 year.
Conclusions: Infections are a frequent complication following
ASCT for HL with serious invasive disease occurring in 11% of pa-
tients. Bacterial infections and CMV antigenemia were the most
common infections in the early post-transplant period, while sino-
pulmonary infections were the most prevalent late infections.139
ORTHOTOPIC HEART TRANSPLANT FACILITATED AUTOLOGOUS HEMA-
TOPOIETIC STEM CELL TRANSPLANTATION IN LIGHT-CHAIN AMYLOID-
OSIS
Kamble, R.T.1, Carrum, G.1, Rice, L.2, McCarthy, J.2, Baker, K.3,
Ramos, C.A.1, Adrogue, H.4, Estep, J.D.5 1Baylor College of Medicine, The
Methodist Hospital, Houston, TX; 2Weill Cornell Medical College, The
Methodist Hospital, Houston, TX; 3The Methodist Hospital, Houston, TX;
4JC Walter Jr Transplant Center, The Methodist Hospital, Houston, TX;
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Dominant cardiac involvement by primary systemic amyloidosis
(AL) precludes effective AL treatment and is associated with short
survival. Three patients who presented with severe cardiac dysfunc-
tion as their major AL manifestation underwent orthotopic heart
S256 Poster Session Itransplantation (OHT) followed by autologous hematopoietic stem
cell transplantation (ASCT).
Age at AL presentation was 63, 62 and 44 years in 2 females and 1
male. Diagnosis of cardiac AL was established via endomyocardial
biopsy, Congo red staining and immunohistochemistry. All had
end stage heart failure with New York Heart Association class 4
symptoms and developed cardiogenic shock requiring intra-aortic
balloon pump support as a bridge to OHT. All were considered un-
suitable for ASCT.
ASCT was performed 13, 16 and 13 months after OHT (table-1).
All 3 patients were on tacrolimus and prednisone at the time of stem
cell mobilization and hematopoietic transplant; two patients were
also receiving mycophenolate mofetil and valganciclovir. We col-
lected 6.1 and 6.2 x 106/kg CD-34+ cells in 2 days with filgrastim
(5 ug/kg, twice, daily) and plerixafor (16 mg/kg based on day- 4
CD-34+ counts) in two subjects. The third initially failed to mobilize
but 4.3x106/kg CD-34+ cells were subsequently obtained when she
(patient #2) was remobilized with filgrastim and plerixafor 4 weeks
after stopping mycophenolate mofetil. The creatinine clearance at
the time of high-dose chemotherapy was 36, 30 and 43 ml/minute.
All 3 patients received renal adjusted dose of melphalan at 140mg/
m2.Mycophenolatemofetil andValganciclovir were withheld during
neutropenia until engraftment. Time to engraftment for neutrophils
(ANC of.500/uL x3 days) was 13, 11 and 14 days. Platelets engraft-
ment (untransfused.20 x 109 for 3 consecutive days) occurred in 14,
13 and 16 days. No patients received post-transplant filgrastim. Pa-
tients were hospitalized for 17, 18 and 18 days. Renal function re-
mained stable during ASCT and non-hematological toxicity was
limited to grade I-II apart from one grade III oral mucositis and co-
litis. One patient achieved hematologic complete remission (pa-
tient#2) while 2 patients had partial response following ASCT.
Post OHT and ASCT all patients are alive and well at follow-up
of 14, 26 and 30 months from OHT.
OHT should be considered in select patients with dominant car-
diac involvement and advanced heart failure to allow subsequent
ASCT and improve survival.
Table. Orthotopic heart transplantation (OHT) followed by
ASCT
Time toAge/
SexTime to
AL diagnosis
(months)Organ
involvementInitial
treatmentTime to
OHT*
(months)ASCT
post OHT
(monthsSurvival
(months)63/F 12 Heart,
kidney,
PNLenalidomide/
dexamethasone7 13 32+62/F 24 Heart,
Kidney,
PNMelphalan/
dexamethasone5 16 26+44/M 12 Heart,
Kidney,
tongueLenalidomide/
dexamethasone4 13 16+*Time to OHT from onset of heart failure symptoms, PN 5 peripheral
nerve, F 5 female, M 5 male140
AUTOLOGOUS STEM CELL TRANSPLANT FOR A PATIENT WITH RELAPS-
ING-REMITTING MULTIPLE SCLEROSIS
Ibrahim, K.A. St Vincent’s Hospital, Sydney, NSW, Australia
Objective: To highlight the use of autologous bone marrow trans-
plantation (BMT) as an option for patients with relapsing-remitting
Multiple Sclerosis.
Clinical Features: A 43-year-old female was diagnosed with Multi-
ple Sclerosis (MS) in 2002. She presented with progressive leg weak-
ness resulting in some impairment of mobility and urinary retention
requiring self-catheterisation. She was commenced on glatiramer ac-
etate with little response. In July 2003 her therapy was changed to in-
terferon from which she had profound side effects. She was switched
back to glatiramer but experienced 3-4 relapses per year. Whilst onglatiramer she became pregnant in 2006. Her MS control was very
good during pregnancy. Nine months after delivery her disease re-
lapsed with further worsening of the right leg weakness and blurring
of the vision in the right eye. In 2009 she underwent treatment with
natalizumab once a month. Initially she had some response to nata-
lizumab but after a year of therapy her disease continued to progress
both clinically and radiologically.
Interventions, Case Progress and Outcome: She was then re-
ferred to the BMT unit for considering autologous stem cell trans-
plant (ASCT) for her condition. In December 2010 she underwent
ASCT with conditioning chemotherapy regimen BEAM (carmus-
tine, etoposide, cytarabine and melphalan) with antithymocyte glob-
ulin (ATG) 20mg/kg for 2 doses. Her transplant course was
complicated by septicaemia with Strep species. Six months after
the ASCT she recovered completely from the procedure and a prog-
ressMRI scan in April 2011 showed significant reduction of the CNS
inflammation and MS lesions. Furthermore she reported significant
improvement in mobility and bladder function.
Conclusions: The use of autologous BMT can be considered as an
option for patients with relapsing-remitting MS who have pro-
gressed on different immunotherapies. Careful selection of patients
with good performance status is crucial as this procedure carries
a 1% mortality risk.141
MULTI-DOSE PHARMACOKINETIC STUDY OF PLERIXAFOR IN A MOR-
BIDLY OBESE PATIENT WITH MULTIPLE MYELOMA AND DIALYSIS-DE-
PENDENT RENAL IMPAIRMENT
Vozniak, J.M.1, Davis, L.E.2, Stadtmauer, E.A.3 1Hospital of the Uni-
versity of Pennsylvania, Philadelphia, PA; 2College of Pharmacy, Univer-
sity of the Sciences, Philadelphia, PA; 3University of Pennsylvania,
Philadelphia, PA
Plerixafor is a CXCR4 antagonist approved formobilization of he-
matopoietic stem cells (HSC) in patients undergoing an autologous
stem cell transplant (AuSCT). Renal dose adjustments are recom-
mended but no data is available for dosing plerixafor in dialysis-de-
pendent patients. To our knowledge no literature describes the
pharmacokinetic (PK) characteristics of plerixafor in patients with
dialysis-dependent renal impairment.
We present a 44-year old morbidly obese (182kg; BMI 61.1) female
with IgGmultiplemyeloma with dialysis-dependent renal impairment
that underwent mobilization with plerixafor and filgrastim. Filgrastim
10mcg/kg/day was initiated 3 days before HSC collection 1. Prior to
plerixafor dosing the patient’s CD34+ 5 9 cells/microL. Plerixafor
started the evening of day 3 andHSCcollection 1 began 11 hours later.
Overall, 3 plerixafor doses were administered. HSC collection 2 began
16 hours after dose 2 and HSC collection 3 began 11 hours following
dose 3. Dialysis (HD) occurred after HSC collections 1 and 3.
Multi-dose PK analysis was conducted (WinNonlin). Data follow-
ing the first dose off HDwere fit to a 2-compartment model with Cl/
F: 3.56 L/hr, V/F: 56.6 L, distribution T1/2: 0.6 hr, and elimination
T1/2: 11 hr. The table summarizes non-compartmental analysis of
each parameter from each day.
Table. Plerixafor Pharmacokinetics by Dose
Apparent ApparentDose
NumberDose
(mg)Tmax
(hr)Cmax
(ng/mL)AUC 0-inf
(ng* hr/mL)Clearance
(L/hr)
Off HDClearance
(L/hr)
On HDHD (4 hr)
Schedule1 27 0.75 602 6406 3.57 10.7 Start 16.4 hr
post-dose2 27 1 665 10919 2.47 – –3 40 1 814 13463 2.16 8.0 Start 17.5 hr
post-doseinf 5 infinity; HD 5 dialysis
HSC collection 1, 2 and 3 yielded 2.2, 2.4 and 3.9 x 106 CD34+
cells/kg, respectively for a total of 8.5 x106 CD34+ cells/kg. Side-
